BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Theratechnologies readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Theratechnologies's drugs run\, f
 rom ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05392114-10797@assetmemo.bio
DTSTAMP:20261121T005628Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Dawnzera (Donidalorsen): Phase 3 readout est. (NCT05392114)
DESCRIPTION:Dawnzera (Donidalorsen)\, phase 3\, Hereditary Angioedema.\nStu
 dy: A Study to Assess the Long-Term Safety and Efficacy of Donidalorsen in
  the Prophylactic Treatment of Hereditary Angioedema (HAE)\nEstimated prim
 ary completion: December 2026. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/donidalorsen#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT05392114
URL:https://assetmemo.bio/drug/donidalorsen#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05681351-1044@assetmemo.bio
DTSTAMP:20261121T005628Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Tryngolza (Olezarsen): Phase 3 readout est. (NCT05681351)
DESCRIPTION:Tryngolza (Olezarsen)\, phase 3\, Severe Hypertriglyceridemia.\
 nStudy: CORE-OLE: A Study of Olezarsen (ISIS 678354) Administered Subcutan
 eously to Participants With Severe Hypertriglyceridemia (SHTG)\nEstimated 
 primary completion: March 2027. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/olezarsen#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT05681351
URL:https://assetmemo.bio/drug/olezarsen#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05185843-1044@assetmemo.bio
DTSTAMP:20261121T005628Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Tryngolza (Olezarsen): Phase 3 readout est. (NCT05185843)
DESCRIPTION:Tryngolza (Olezarsen)\, phase 3\, Familial Chylomicronemia Synd
 rome.\nStudy: A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRX) A
 dministered to Adults With Familial Chylomicronemia Syndrome (FCS) Previou
 sly Treated With Volanesorsen\nEstimated primary completion: June 2027. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/olezarsen#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT05185843
URL:https://assetmemo.bio/drug/olezarsen#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05130450-1044@assetmemo.bio
DTSTAMP:20261121T005628Z
DTSTART;VALUE=DATE:20280229
DTEND;VALUE=DATE:20280301
SUMMARY:Tryngolza (Olezarsen): Phase 3 readout est. (NCT05130450)
DESCRIPTION:Tryngolza (Olezarsen)\, phase 3\, Familial Chylomicronemia Synd
 rome.\nStudy: A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRx) i
 n Participants With Familial Chylomicronemia Syndrome (FCS)\nEstimated pri
 mary completion: February 2028. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/olezarsen#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT05130450
URL:https://assetmemo.bio/drug/olezarsen#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07298447-10797@assetmemo.bio
DTSTAMP:20261121T005628Z
DTSTART;VALUE=DATE:20290630
DTEND;VALUE=DATE:20290701
SUMMARY:Dawnzera (Donidalorsen): Phase 3 readout est. (NCT07298447)
DESCRIPTION:Dawnzera (Donidalorsen)\, phase 3\, Hereditary Angioedema.\nStu
 dy: Donidalorsen Treatment in Children With Hereditary Angioedema\nEstimat
 ed primary completion: June 2029. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/donidalorsen#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT07298447
URL:https://assetmemo.bio/drug/donidalorsen#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07727538-1044@assetmemo.bio
DTSTAMP:20261121T005628Z
DTSTART;VALUE=DATE:20300831
DTEND;VALUE=DATE:20300901
SUMMARY:Tryngolza (Olezarsen): Phase 3 readout est. (NCT07727538)
DESCRIPTION:Tryngolza (Olezarsen)\, phase 3\, Familial Chylomicronemia Synd
 rome.\nStudy: A Study of Olezarsen for the Treatment of Familial Chylomicr
 onemia Syndrome (FCS) in Pediatric Participants\nEstimated primary complet
 ion: August 2030. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ole
 zarsen#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT07727538
URL:https://assetmemo.bio/drug/olezarsen#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
